Pharmaceutical
Human APIs Powder
- Respiratory Drugs Raw Material
- Antiviral Antibacterial
- Antipyretic Analgesics
- Antihistamine Drugs
- Antineoplastic
- Cosmetic Raw Material
OEM & ODM
Veterinary raw materials
Phone: 86-29-89601602
E-mail: sales21@interlgroup.com
Add: Fengcheng 2nd Road, Weiyang District, Xi'an, Shaanxi, China
Mycophenolate Mofetil Raw material powder
Product Overview:
Mycophenol morpheate, also known as mycophenolate ester (MMF), trade name Cellcept, developed by Syntex Company in the United States, is a semi-synthetic derivative of mycophenolic acid (MPA) isolated from the ferment of mold Penicillinglaucum. Mycophenolate is a reversible cell inhibitor, in fact, it has been clinically used for more than 10 years, mainly for the treatment of psoriasis. In the late 1980s, animal experiments on organ transplantation proved that it could significantly prolong the survival time of kidney, heart and islet allografts in rodents and dogs
Mycophenolate Mofetil Raw material powder Attributes
CAS:115007-34-6
MF:C23H31NO7
MW:433.49
EINECS:680-628-5
Specification: 99% min Mycophenolate Mofetil powder
Sample:Mycophenolate Mofetil powder
Packaging:1kg/bag, 25kg/drum
Brand: Henrikang
Appearance:white
Storage: Cool Dry Place
Shelf Life: 2 Years
Test Method: HPLC
Mycophenolate Mofetil Raw material powder Details
Mycophenolate Mofetil Powder Usage and Synthesis.
Morpholine ethyl mycophenolate is an immunosuppressant used in organ transplantation and is also used to treat autoimmune myasthenia gravis (MG).
Uses of Mycophenolate Mofetil.
It is mainly used to prevent allogeneic organ rejection. It is mainly used for kidney transplantation, but also for heart and liver transplantation, especially for refractory rejection after transplantation. It can be used simultaneously with cyclosporine and corticosteroids. It can also be used in rheumatoid arthritis, systemic lupus erythematosus, primary glomerulonephritis, psoriasis and other autoimmune diseases. Oral: Kidney transplantation: the initial dose is 2 to 3mg/kg per day, and the maintenance dose is 1 to 2mg/kg per day, divided into 2 to 3 times. Can be adjusted according to the condition.
Pharmacological action of Mycophenolate Mofetil.
Mycophenolate morpheate is quickly absorbed in the upper digestive tract after oral administration. The main site of absorption is in the stomach and is metabolized by plasma lipase into the pharmacologically active product enzyme phenolic acid (MPA) with an average bioavailability of 94%. The blood concentration quickly peaked 1 hour after taking the drug, and then rapidly decreased. MPA is metabolized in the liver to a stable, pharmacologically inactive glucuronide (MPAG) by gluconaldehyde acidification and excreted in the urine.
MPAG excreted in the intestine through bile enters the small intestine, where it is converted into MPA by the glucosidase of the intestinal flora, which is reabsorbed through the intestine, forming enterohepatic circulation, and a second plasma MPA peak occurs (6-12 hours after administration). About 6% of MPAG is excreted in the stool. It is activated by hydrolytic metabolism in vivo, non-competitively inhibits hypoxanthine dehydrogenase monophosphate and blocks guanine nucleotide synthesis, thus exerting its immunosuppressive effect on lymphocytes, and T lymphocytes and B lymphocytes are significantly affected by it.
Product Method of Bulk Mycophenolate Mofetil Powder.
